Synthego: $1B valuation, IPO Readiness 58, Series E. Genome engineering company providing synthetic RNA and CRISPR tools that accelerate genomic research. Track live on The IPO Stack.
Genome engineering company providing synthetic RNA and CRISPR tools that accelerate genomic research.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Synthego IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Synthego has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Synthego is valued at $1B as of March 2021. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Synthego shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Synthego scores 58/100 (Grade: C) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Synthego has raised $450M in total venture capital and private equity funding, with backing from Softbank Vision Fund, GV, ARCH Venture Partners.
Synthego's notable investors include Softbank Vision Fund, GV, ARCH Venture Partners, 8VC. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Synthego is a Biotechnology company. Genome engineering company providing synthetic RNA and CRISPR tools that accelerate genomic research.